[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 251,428
  • Shares Outstanding, K 154,250
  • Annual Sales, $ 42,170 K
  • Annual Income, $ 168,020 K
  • EBIT $ -181 M
  • EBITDA $ -177 M
  • 60-Month Beta 1.01
  • Price/Sales 6.24
  • Price/Cash Flow N/A
  • Price/Book 3.35

Options Overview Details

View History
  • Implied Volatility 145.24% (-48.61%)
  • Historical Volatility 69.30%
  • IV Percentile 18%
  • IV Rank 9.57%
  • IV High 670.52% on 11/17/25
  • IV Low 89.67% on 08/13/25
  • Expected Move (DTE 34) 0.0850 (5.21%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 104
  • Volume Avg (30-Day) 227
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 17,876
  • Open Int (30-Day) 16,837
  • Expected Range 1.5450 to 1.7150

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 1
  • High Estimate $-0.28
  • Low Estimate $-0.28
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) +28.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +1.87%
on 05/13/26
2.1050 -22.57%
on 05/11/26
-0.2500 (-13.30%)
since 04/15/26
3-Month
1.5200 +7.24%
on 03/20/26
2.1050 -22.57%
on 05/11/26
+0.0200 (+1.24%)
since 02/13/26
52-Week
0.7100 +129.58%
on 06/23/25
2.6158 -37.69%
on 01/27/26
+0.8620 (+112.24%)
since 05/15/25

Most Recent Stories

More News
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

CHRS : 1.6300 (unch)
GTBP : 0.4399 (+0.23%)
FATE : 1.9000 (-11.01%)
ARTV : 11.11 (+4.03%)
IBRX : 7.94 (-2.53%)
Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts...

CHRS : 1.6300 (unch)
Coherus Oncology: Q1 Earnings Snapshot

Coherus Oncology: Q1 Earnings Snapshot

CHRS : 1.6300 (unch)
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking...

CHRS : 1.6300 (unch)
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday,...

CHRS : 1.6300 (unch)
Coherus Oncology: Q4 Earnings Snapshot

Coherus Oncology: Q4 Earnings Snapshot

CHRS : 1.6300 (unch)
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025...

CHRS : 1.6300 (unch)
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market...

CHRS : 1.6300 (unch)
Coherus Oncology to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations...

CHRS : 1.6300 (unch)
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE)...

CHRS : 1.6300 (unch)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.8117
2nd Resistance Point 1.7733
1st Resistance Point 1.7017
Last Price 1.6300
1st Support Level 1.5917
2nd Support Level 1.5533
3rd Support Level 1.4817

See More

52-Week High 2.6158
Fibonacci 61.8% 1.8878
Fibonacci 50% 1.6629
Last Price 1.6300
Fibonacci 38.2% 1.4380
52-Week Low 0.7100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.